Anabolic–androgenic steroids: How do they work and what are the risks?
Anabolic–androgenic steroids (AAS) are a class of hormones that are widely abused for
their muscle-building and strength-increasing properties in high, nontherapeutic, dosages …
their muscle-building and strength-increasing properties in high, nontherapeutic, dosages …
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
T Barbui, J Thiele, H Gisslinger, HM Kvasnicka… - Blood cancer …, 2018 - nature.com
The new edition of the 2016 World Health Organization (WHO) classification system for
tumors of the hematopoietic and lymphoid tissues was published in September 2017. Under …
tumors of the hematopoietic and lymphoid tissues was published in September 2017. Under …
Guidelines on the Use of therapeutic apheresis in clinical practice–Evidence‐Based approach from the Writing Committee of the American Society for Apheresis: The …
L Connelly‐Smith, CR Alquist, NA Aqui… - Journal of clinical …, 2023 - Wiley Online Library
Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Guidelines on the use of therapeutic apheresis in clinical practice–evidence‐based approach from the Writing Committee of the American Society for Apheresis: the …
A Padmanabhan, L Connelly‐Smith… - Journal of clinical …, 2019 - Wiley Online Library
ABSTRACT The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating and categorizing …
Special Issue Writing Committee is charged with reviewing, updating and categorizing …
Rusfertide, a hepcidin mimetic, for control of erythrocytosis in polycythemia vera
M Kremyanskaya, AT Kuykendall… - … England Journal of …, 2024 - Mass Medical Soc
Background Polycythemia vera is a chronic myeloproliferative neoplasm characterized by
erythrocytosis. Rusfertide, an injectable peptide mimetic of the master iron regulatory …
erythrocytosis. Rusfertide, an injectable peptide mimetic of the master iron regulatory …
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
This document updates the recommendations on the management of Philadelphia
chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) published in 2011 by …
chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) published in 2011 by …
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views
Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that
exceeds 35 years in young patients, but its natural history might be interrupted by …
exceeds 35 years in young patients, but its natural history might be interrupted by …
Guidelines on the use of therapeutic apheresis in clinical practice–evidence‐based approach from the writing committee of the American society for apheresis: the …
J Schwartz, A Padmanabhan, N Aqui… - Journal of clinical …, 2016 - Wiley Online Library
The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA) Special
Issue Writing Committee is charged with reviewing, updating, and categorizing indications …
Issue Writing Committee is charged with reviewing, updating, and categorizing indications …
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations
M Marchetti, AM Vannucchi, M Griesshammer… - The Lancet …, 2022 - thelancet.com
Polycythaemia vera is associated with a reduced quality of life, a high rate of vascular
events, and an intrinsic risk of disease evolution. The results of several randomised trials for …
events, and an intrinsic risk of disease evolution. The results of several randomised trials for …
Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management
Abstract Disease Overview Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative
neoplasm characterized by clonal erythrocytosis; other features include leukocytosis …
neoplasm characterized by clonal erythrocytosis; other features include leukocytosis …